Literature DB >> 7620005

Characteristics of and risk factors for relapse of brucellosis in humans.

J Ariza1, J Corredoira, R Pallares, P F Viladrich, G Rufi, M Pujol, F Gudiol.   

Abstract

For 16 years we prospectively observed 530 adult patients with brucellosis to analyze the characteristics of and risk factors for relapse. Clinical and laboratory findings from 86 relapsed patients were milder during the relapse episode when compared with those for the same patients during the initial disease. Blood cultures were positive for Brucella melitensis in 65% of cases during relapse and in approximately 80% of cases during the initial disease. Risk factors that were identified as being independently associated with relapse (by logistic regression analysis) were "less-effective" antibiotic therapy (OR, 8.3; 95% CI, 4.6-15.1), positive blood cultures during initial disease (OR, 2.7; 95% CI, 1.2-6.2), < or = 10-day duration of the disease before treatment (OR, 1.9; 95% CI, 1.1-3.6), male sex (OR, 1.8; 95% CI, 1.02-3.8) and a platelet count of < or = 150 x 10(3)/mm3 (OR, 1.7; 95% CI, 1.1-2.8). These data show that relapse of brucellosis is sometimes difficult to diagnose and that it can be an insidious disease. In addition to inappropriate antibiotic therapy, other factors, such as those indicating a more aggressive disease and/or a deficient immunologic response, seem to play an important role in the relapse of brucellosis.

Entities:  

Mesh:

Year:  1995        PMID: 7620005     DOI: 10.1093/clinids/20.5.1241

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Posttreatment follow-Up of brucellosis by PCR assay.

Authors:  P Morata; M I Queipo-Ortuño; J M Reguera; M A García-Ordoñez; C Pichardo; J D Colmenero
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Effect of early antibiotic treatment on the antibody response to cytoplasmic proteins of Brucella melitensis in mice.

Authors:  R A Bowden; G C Racaro; P C Baldi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Evaluation of conventional castaneda and lysis centrifugation blood culture techniques for diagnosis of human brucellosis.

Authors:  Basappa G Mantur; Smita S Mangalgi
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

4.  Prevalence of Brucella antibodies on a previously acute brucellosis infected population: sensitivity, specificity and predictive values of Rose Bengal and Wright standard tube agglutination tests.

Authors:  Panagiotis Andriopoulos; Antonia Kalogerakou; Dimitra Rebelou; Andrea Paola Rojas Gil; Sofia Zyga; Vassiliki Gennimata; Maria Tsironi
Journal:  Infection       Date:  2015-02-28       Impact factor: 3.553

5.  Bacteremic and nonbacteremic brucellosis: clinical and laboratory observations.

Authors:  A Kadanali; K Ozden; U Altoparlak; A Erturk; M Parlak
Journal:  Infection       Date:  2009-01-12       Impact factor: 3.553

6.  Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.

Authors:  Beata Clapp; Jerod A Skyberg; Xinghong Yang; Theresa Thornburg; Nancy Walters; David W Pascual
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

Review 7.  Alternative strategies for vaccination to brucellosis.

Authors:  David W Pascual; Xinghong Yang; Hongbin Wang; Zakia Goodwin; Carol Hoffman; Beata Clapp
Journal:  Microbes Infect       Date:  2017-12-26       Impact factor: 2.700

8.  Acute prostatitis as an uncommon presentation of brucellosis.

Authors:  Elif Hakko; Melda Ozdamar; Salih Turkoglu; Semra Calangu
Journal:  BMJ Case Rep       Date:  2009-05-25

Review 9.  Laboratory Diagnosis of Human Brucellosis.

Authors:  Pablo Yagupsky; Pilar Morata; Juan D Colmenero
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

10.  Development and evaluation of a PCR-enzyme-linked immunosorbent assay for diagnosis of human brucellosis.

Authors:  Pilar Morata; María I Queipo-Ortuño; Jose M Reguera; Miguel A García-Ordoñez; Ana Cárdenas; Juan D Colmenero
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.